Cancer clinical trials in the region Île-de-France
768 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT07357727
#2025-523555-66-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
Allogeneic stem cell transplant
12 recruiting sites
Novartis Pharmaceuticals
Phase 3
Skin cancer
#NCT06264180
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Replimune
Phase 3
Stomach and esophageal cancer
#NCT06644781
#2023-509630-19-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
18 recruiting sites
Daiichi Sankyo
Phase 3
Prostate cancer
#NCT06136650
#2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie B (Mutation T315I)
Required disease stage
Chronic phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie A (Non-T315I)
Required disease stage
Chronic phase
Required number of previous lines of therapy
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Breast cancer
#NCT07492641
#2025-523960-19-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
BeOne Medecines
Phase 3
Breast cancer
#NCT07492641
#2025-523960-19-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
BeOne Medecines
Phase 3
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Skin cancer
#NCT06471465
#2024-510893-25-00
Required previous treatments at localized stage
Radiotherapy
10 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 3
Colon cancer
Rectal cancer
#NCT06501482
#2023-504831-42-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Assistance Publique - Hôpitaux de Paris